Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

StatusActive, Not Recruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Dec 31, 2025 → Dec 31, 2026
See other at-risk trials from Seoul National University Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Dec 31, 2025 to Dec 31, 2026
    • Eligibility criteria expanded, about 43 words
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Primary completion date: Dec 30, 2021 to Dec 31, 2025
    • Study completion date: Dec 30, 2022 to Dec 31, 2025
    v3
  3. Primary completion date: Apr 30, 2020 to Dec 30, 2021v2 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 25 to confirmed 54
    • Study completion date: Apr 30, 2020 to Dec 30, 2022
    • Site details revised
  4. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Window of Opportunity Trial of Olaparib and Durvalumab (MEDI4736) before Standard Neoadjuvant Chemotherapy for Stage II/III Triple Negative or Low ER+ Breast Cancer
Trial Details
NCT Number NCT03594396
Lead Sponsor Seoul National University Hospital
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Breast Neoplasms
Related terms Breast Neoplasms
Enrollment 54 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov